Crinetics Pharmaceuticals (CRNX) Total Non-Current Liabilities (2017 - 2026)

Crinetics Pharmaceuticals' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $115.8 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 9.65% year-over-year to $115.8 million; the TTM figure through Mar 2026 stood at $115.8 million (up 9.65% YoY), while the FY2025 annual figure was $130.9 million, up 20.17% from the prior year.
• Total Non-Current Liabilities was $115.8 million for Q1 2026 at Crinetics Pharmaceuticals, down from $130.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $130.9 million in Q4 2025 to a low of $96.2 million in Q4 2023.
• Historically, Total Non-Current Liabilities has averaged $111.4 million across 4 years, with a median of $109.0 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities advanced 20.17% in 2025, then climbed 9.65% in 2026.
• A 4-year view of Total Non-Current Liabilities shows it stood at $96.2 million in 2023, then climbed by 13.21% to $109.0 million in 2024, then climbed by 20.17% to $130.9 million in 2025, then slipped by 11.6% to $115.8 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $115.8 million (Q1 2026), $130.9 million (Q4 2025), and $121.0 million (Q3 2025), per Business Quant data.